var data={"title":"Factor XIII, concentrate from human plasma: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor XIII, concentrate from human plasma: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/461270?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-xiii-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;Factor XIII, concentrate from human plasma: Drug information&quot;</a> and <a href=\"topic.htm?path=factor-xiii-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor XIII, concentrate from human plasma: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12871939\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Corifact</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27746314\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Corifact</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14856201\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14856208\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=factor-xiii-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;Factor XIII, concentrate from human plasma: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Congenital factor XIII deficiency:</b> Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylaxis: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 40 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Adjust dose in 5 units/kg increments  based on factor XIII activity trough levels (target level of 5% to 20% using Berichrom activity assay) and clinical response; repeat every 28 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Factor XIII Activity Trough Level (%): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">One trough level &lt;5%: Increase dosage by 5 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Trough level 5% to 20%: No dosage change </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Two trough levels &gt;20%: Decrease dosage by 5 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">One trough level &gt;25%: Decrease dosage by 5 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment, perioperative management of surgical bleeding:</i> Individualize dosing based on factor XIII activity level, type of surgery, and clinical response; monitor factor XIII activity levels during and after surgery: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If time since last prophylactic dose &le;7 days: Additional dose may not be needed. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If time since last prophylactic dose 8 to 21 days: Additional partial or full dose may be necessary based on factor XIII activity level.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If time since last prophylactic dose 21 to 28 days: Administer full prophylactic dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Congenital factor XIII deficiency:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylaxis: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 40 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Dose adjustment should be based on factor XIII activity trough levels (target level of 5% to 20% using Berichrom activity assay) and clinical response; repeat every 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">One trough level &lt;5%: Increase dosage by 5 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Trough level 5% to 20%: No dosage change </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Two trough levels &gt;20%: Decrease dosage by 5 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">One trough level &gt;25%: Decrease dosage by 5 units/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Perioperative management of surgical bleeding:</i> Individualize dosing based on factor XIII activity level, type of surgery, and clinical response; monitor factor XIII activity levels during and after surgery: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If time since last prophylactic dose &le;7 days: Additional dose may not be needed. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If time since last prophylactic dose 8 to 21 days: Additional partial or full dose may be necessary based on factor XIII activity level.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If time since last prophylactic dose 21 to 28 days: Administer full prophylactic dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12871940\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Corifact: 1000 - 1600 units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595705\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51237131\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=factor-xiii-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;Factor XIII, concentrate from human plasma: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">Potency is shown as a range for each vial. The actual units of potency of FXIII are stated on each vial label and carton.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14856209\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer by IV infusion at a rate not to exceed 4 mL/minute. Product should be brought to room temperature prior to infusing. Administer through a separate infusion line.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595754\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. May be stored at room temperature (&le;25&deg;C [&le;77&deg;F]) for up to 6 months; do not return to refrigerator if stored at room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14856202\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prophylaxis against bleeding episodes and management of perioperative surgical bleeding in patients with congenital factor XIII deficiency (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595805\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor XIII may be confused with Factor VIII</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595750\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hematoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, antibody development (factor XIII), infection, ischemia (acute), thromboembolism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595712\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of anaphylaxis or severe systemic reactions to human plasma-derived products or hypersensitivity to any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595713\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: The development of factor XIII inhibitory antibodies has been reported.  Factor XIII inhibitory antibodies should be measured when clinical response (breakthrough bleeding) and/or factor XIII trough levels are suboptimal after apparent adequate dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions have been reported with use; discontinue immediately if develops and initiate appropriate management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Thromboembolic events have been reported; pregnant women may be at increased risk due to hypercoagulable state. Use with caution in patients with known risk factors for thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Vaccination with hepatitis A and hepatitis B vaccines is  recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299310\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12608729\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105600&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595709\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595710\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use in pregnant women only when benefit exceeds potential risk to the fetus. Thromboembolic events have been reported with use of factor XIII; pregnant women may be at increased risk due to hypercoagulable state.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14856210\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Factor XIII trough levels in conjunction with clinical response to assess efficacy (ie, approximately every 28 days for prophylaxis, during and after surgery for perioperative management of surgical bleeding). Factor XIII inhibitory antibodies if inadequate clinical response and/or factor XIII trough levels are suboptimal. Signs/symptoms of hypersensitivity reactions, thrombotic events, and infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595756\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Factor XIII (FXIII) is an endogenous plasma glycoprotein found in platelets, monocytes and macrophages that is converted to activated factor XIII (FXIIIa) in the presence of calcium ions.  Once activated, FXIIIa cross-links fibrin and cross-links plasmin inhibitor to protect and strengthen the hemostatic platelet plug.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595758\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of effect: Plasma levels of FXIII: ~28 days; FXIII activity maintained at &ge;5% in &ge;97% of patients and &ge;10% in &ge;85% of patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 51.1 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Factor XIII, a proenzyme, is converted to activated factor XIII</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Children (&lt;16 years): 5.7 &plusmn; 1 days; Adults: 7.1 &plusmn; 2.7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1.7 hours postinfusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Clearance: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients &lt;16 years: 0.29 &plusmn; 0.12 mL/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.22 &plusmn; 0.07 mL/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121601\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Corifact Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000-1600 unit (Price provided is per AHF Unit): $11.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992821\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Fibrogammim (LT);</li>\n      <li>Fibrogammin (AT, DE, FR, GR, LU);</li>\n      <li>Fibrogammin P (AR, AU, BR, CH, CZ, GB, HK, IL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Corifact (factor xiii concentrate [human]) [prescribing information]. Kankakee, IL: CSL Behring, LLC; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsieh L and Nugent D, &ldquo;Factor XIII Deficiency,&rdquo; <i>Haemophilia</i>, 2008, 14(6):1190-200.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karimi M, Bereczky Z, Cohan N, et al, &ldquo;Factor XIII Deficiency,&rdquo; <i>Semin Thromb Hemost</i>, 2009, 35(4):426-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-xiii-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/19598071/pubmed\" target=\"_blank\" id=\"19598071\">19598071</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105600 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F12871939\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F27746314\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F14856201\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F14856208\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F12871940\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F11595705\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F51237131\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14856209\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F11595754\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14856202\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11595805\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11595750\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11595712\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11595713\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299310\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F12608729\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F11595709\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11595710\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14856210\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11595756\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F11595758\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21121601\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992821\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/105600|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-xiii-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">Factor XIII, concentrate from human plasma: Drug information</a></li><li><a href=\"topic.htm?path=factor-xiii-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">Factor XIII, concentrate from human plasma: Patient drug information</a></li></ul></div></div>","javascript":null}